Audit Target – Pre-Filled Injectable Pens and Syringes

Audit Target – Pre-Filled Injectable Pens and Syringes

Pre-filled injectable medication such as insulin, Invega®, Humira®, Enbrel® and Ozempic® remain a big target for audit risk due to their high cost and potential billing pitfalls. One claim error can cost you thousands of dollars. PAAS National® often sees prescriptions for pre-filled injectable medications flagged for recoupment due to one or more of the following reasons:

Become an audit assistance member today to continue reading this article. As a member, you’ll have access to hundreds of articles and receive our monthly proactive newsletter!

  1. Missing a unit of measure (UOM) or written for a UOM that does not make sense
  2. Missing dosage or quantity to inject
  3. Missing the route of administration (ROA)
  4. Missing calculable instructions/frequency

PAAS Tips:

  • Here is a Humira prescription example:
    • The quantity of #1 could be interpreted as 1 pen when the box comes as a kit and contains 2 pens
    • There is no UOM, so does the prescriber want 1 box, 1 mL, 1 pen, 1 kit?
    • The SIG does not contain calculable instructions = how much to inject, where to inject (ROA) or how often to inject
  • If the pharmacy received this prescription and did not clarify any elements, it would be marked discrepant upon audit.
  • Upon receiving this prescription, ideally, the pharmacy would clarify the following elements with the prescriber’s office and make a clinical notation
    • Quantity of 1 = 1 kit or 2 pens
    • SIG – Inject 40 mg subcutaneously once a week – this clarifies how much to inject, the ROA and how often to inject
  • Utilize the PAAS National® Self-Audit Mindset tool when reviewing prescription
  • Pay special attention to pre-filled injectable pens and syringes to avoid thousands of dollars of chargebacks upon an audit

Jennifer Ottman, CPhT